Document text
Principal Investigator: Andrew Ben Stergachis
Organization: UNIVERSITY OF WASHINGTON
Fiscal Year: 2024
Award: $388,750
Funding agency: NIH Office of the Director
PROJECT SUMMARY/ABSTRACT
Genetic testing is rapidly emerging as a cornerstone of medicine, enabling targeted therapies for patients with
both common and rare disorders, and empowering patients, families and communities with knowledge about
their condition. However, despite significant advances over the past decade, including the introduction of
clinical whole genome sequencing, clinical genetics remains largely limited to the study of less than 1% of the
genome, the exome. This limitation is thought to underlie the fact that clinical genomic sequencing is
unsuccessful in elucidating the culprit pathogenic variant(s) for the majority of patients with presumed
monogenic disorders who undergo testing. It is hypothesized that a significant percentage of these patients
harbor pathogenic non-coding variants that disrupt the gene regulatory architecture of known Mendelian
genes, a class of variants poorly illuminated using current sequencing approaches. Directly addressing this
limitation requires a wholesale revision of how genetic testing is performed and interpreted, as is outlined in
this proposal. Specifically, this proposal aims to overcome this fundamental limitation of human genetics by
leveraging a novel approach we recently developed for simultaneously mapping the genetic and epigenetic
landscape of a sample, thereby illuminating the functional impact of non-coding genetic variants that disrupt
local chromatin architecture and gene regulatory patterns – Whole Epi-Genome Sequencing (WEGS). Using
this approach, we plan to directly test the hypothesis that rare non-coding genetic alterations contribute to
monogenic disorders. In Aim 1, we will use the WEGS approach to characterize the gene regulatory impact of
non-coding sequence, structural and epigenetic alterations in healthy individuals as well as patients with known
imprinting disorders. The goal of this aim is to establish the sensitivity and power of WEGS for identifying
genetic variants that disrupt local chromatin architecture and gene regulatory patterns and improve our
understanding of the functional impact of non-coding genetic variation. In Aim 2, we will directly evaluate the
contribution of rare non-coding genetic alterations to monogenic disorders by applying WEGS to patients with
suspected monogenic disorders for whom whole exome or genome sequencing has previously been non-
diagnostic. Overall, this proposal has the potential to dramatically change how we approach genomic testing
and our understanding of the impact of non-coding sequence and structural variation on gene regulatory
patterns and human disease.
Terms: <Address><Appointment><Architecture><Area><Award><Causality><Chromatin><Chromosome Mapping><Clinical><Clinical genetics><Communities><Complex><Defect><Disease><Disorder><Engineering / Architecture><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Etiology><Family><Financial Support><Functional RNA><Gene Localization><Gene Mapping><Gene Mapping Genetics><Gene variant><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic Diversity><Genetic Variation><Genetic defect><Genome><Genomic approach><Genomic medicine><Genomics><Goals><Human><Human Genetics><Individual><Institution><Knowledge><Lead><Linkage Mapping><Medical><Medical Genetics><Medicine><Mendelian disease><Mendelian disorder><Mendelian genetic disorder><Modern Man><Mutation><NIH><National Institutes of Health><Non-Coding><Non-Coding RNA><Non-translated RNA><Noncoding RNA><Nontranslated RNA><Nucleotides><Orphan Disease><Pathogenicity><Patients><Pattern><Pb element><Persons><Phenotype><Position><Positioning Attribute><Postdoc><Postdoctoral Fellow><Rare Diseases><Rare Disorder><Research><Research Associate><Research Proposals><Research Resources><Resolution><Resources><Role><Sampling><Scientist><Sequence Homology><Single Base Polymorphism><Single Nucleotide Polymorphism><Technology><Testing><Total Human and Non-Human Gene Mapping><United States National Institutes of Health><Untranslated RNA><Variant><Variation><allele variant><allelic variant><causation><clinical training><disease causation><disease causing variant><disease-causing mutation><empowerment><entire genome><epigenetically><epigenome><exome><exome sequencing><exome-seq><exomes><financial assistance><full genome><gene testing><gene-based testing><genetic mapping><genetic testing><genetic variant><genome mutation><genome sequencing><genomic effort><genomic strategy><genomic variant><heavy metal Pb><heavy metal lead><human disease><imprint><improved><lab equipment><laboratory equipment><laboratory technology><monogenic disease><monogenic disorder><new approaches><noncoding><novel approaches><novel strategies><novel strategy><orphan disorder><pathogenic variant><post-doc><post-doctoral><post-doctoral trainee><professor><research associates><resolutions><single nucleotide variant><single-gene disease><single-gene disorder><social role><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><translational genomics><whole genome>